Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-17, Stock:ABBV, The news for the past five days is as follows:
2018-07-10: NEWS1: The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie.NEWS2: The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie.NEWS3: Ex-Dividend Reminder: AbbVie, Abbott Laboratories and Patterson Companies.NEWS4: Ex-Dividend Reminder: AbbVie, Abbott Laboratories and Patterson Companies.NEWS5: The Zacks Analyst Blog Highlights: Apache, Continental Resources, KMG Chemicals, ZAGG and AbbVie.NEWS6: AbbVie to Host Second-Quarter 2018 Earnings Conference Call.
2018-07-11: NEWS1: Top 5 Biotech Stocks for 2018.NEWS2: Stocks to Watch: Boeing, Ford, American Airlines, JetBlue, Pfizer, Comcast, Alphabet, Nvidia, AbbVie.NEWS3: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2018.NEWS4: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for July 12, 2018.NEWS5: AbbVie&apos;s stock falls after lymphoma treatment trial data disappoints.NEWS6: AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) and Ongoing Ibrutinib Clinical Program.NEWS7: Ex-Dividend Alert: AbbVie Has Raised its Dividend By 140% Since 2013; Will Trade Ex-Dividend on July 12, 2018.NEWS8: AbbVie Updates On Phase 3 Study Of Ibrutinib In Blood Cancer DLBCL.NEWS9: AbbVie Updates On Phase 3 Study Of Ibrutinib In Blood Cancer DLBCL.
2018-07-12: NEWS1: 3 Pharma Stocks Goldman Sachs Sees as Buys.NEWS2: AbbVie's Imbruvica Fails in Phase III Blood Cancer Study.NEWS3: AbbVie's Imbruvica Fails in Phase III Blood Cancer Study.NEWS4: Keep Your Eyes on Healthcare's Odd Couple: AbbVie and Alphabet.NEWS5: Keep Your Eyes on Healthcare's Odd Couple: AbbVie and Alphabet.NEWS6: AbbVie&apos;s Imbruvica Fails in Phase III Blood Cancer Study.NEWS7: J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What&apos;s Up?.NEWS8: Keep Your Eyes on Healthcare&apos;s Odd Couple: AbbVie and Alphabet.NEWS9: Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial.NEWS10: AbbVie Gives Disappointing Update on Imbruvica Study.NEWS11: [$$] The drug pricing playbook: how pharma companies keep costs high.NEWS12: AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy.NEWS13: Genentech Announces Submission Of SNDA For Venclexta - Quick Facts.NEWS14: Genentech Announces Submission Of SNDA For Venclexta - Quick Facts.
2018-07-13: NEWS1: AbbVie Announces Collaborations with Calico and Calibr.NEWS2: AbbVie’s Supplemental New Drug Application for Venetoclax.NEWS3: 5 Big Pharma Stocks Investors Love Right Now.NEWS4: 5 Big Pharma Stocks Investors Love Right Now.NEWS5: 2 Overlooked Biotech Stocks to Buy Now.NEWS6: 2 Overlooked Biotech Stocks to Buy Now.NEWS7: Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?.NEWS8: Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?.NEWS9: 5 Big Pharma Stocks Investors Love Right Now.NEWS10: Will J&J&apos;s (JNJ) Pharma Segment Strength Drive Q2 Earnings?.NEWS11: Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit.NEWS12: 2 Overlooked Biotech Stocks to Buy Now.
2018-07-16: nan

Answer: Decrease